Event context and why Hologic is on investors’ radar
Hologic (HOLX) is back in focus after recent trading left the shares near US$75.59. This has put fresh attention on how its current valuation lines up with fundamentals across diagnostics, breast health, and surgical products.
See our latest analysis for Hologic.
Recent trading has been fairly steady, with the 1 year total shareholder return of 15.19% contrasting with a 3 year total shareholder return decline of 3.46%, which suggests momentum has recently improved even as longer term results remain mixed.
If Hologic’s move has you rethinking where growth in healthcare could come from next, it might be worth scanning 32 healthcare AI stocks as a starting list of ideas.
So, with Hologic trading near US$75.59, an intrinsic discount of about 30%, recent annual revenue and net income growth, and the share price only slightly below analyst targets, is this a mispriced healthcare name, or is the market already baking in future gains?
Most Popular Narrative: 1.3% Undervalued
The most followed narrative on Hologic pegs fair value at $76.60, a touch above the recent $75.59 close. It builds its case around cash flows discounted at roughly 8%.
The analysts have a consensus price target of $73.867 for Hologic based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $94.0, and the most bearish reporting a price target of just $65.0.
Want to see what is sitting behind that tight fair value range and modest discount? Revenue, margins and future P/E assumptions all pull weight here, but in very specific ways the headline target alone does not show.
Result: Fair Value of $76.60 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, risks around China revenue pressure and ongoing tariff costs could still unsettle earnings expectations and challenge the current undervalued narrative if they persist.
Find out about the key risks to this Hologic narrative.
Another angle on Hologic’s valuation
On simple earnings multiples, Hologic looks less clear cut. The P/E sits around 31x, slightly above the US Medical Equipment industry at 27.6x and almost exactly in line with a 30.7x fair ratio estimate. That points to only modest valuation room either way. So is the 30% DCF discount really there for the taking?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this combination of fair value signals and recent returns leaves you undecided, it may be helpful to act now and carefully consider both sides of the story using 2 key rewards and 1 important warning sign.
Looking for more investment ideas?
If Hologic has sharpened your focus on where to put your next dollar, do not stop here; broader opportunities could be one smart screener away.
- Spot potential value candidates early by running your eye over 46 high quality undervalued stocks that pair fundamentals with attractive pricing signals.
- Strengthen the core of your portfolio by checking companies in the solid balance sheet and fundamentals stocks screener (41 results) that prioritize financial resilience.
- Hunt for lesser known opportunities before the crowd by scanning the screener containing 23 high quality undiscovered gems with strong underlying metrics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com